08.04.2013 • News

Gelest Announces New Appointments

Gelest is pleased to announce a number of new appointments and promotions it has recently made to drive and support its growth as a manufacturer and supplier of silane, silicone and metal-organic compounds to the global marketplace.

Key appointments

Greg Hertenberger has joined Gelest as Product Manager Silanes and Metal-Organics. His responsibilities include development of new business for Gelest's wide range of functional and non-functional alkyl silane compounds and for the company's greatly expanded range of metal-organic compounds for materials, polymers and synthesis.

Matthew Suits has joined Gelest as Facilities Manager. His responsibilities include managing new construction for Gelest as well as its maintenance department. Previously, he was an Engineering and Process Manager at PB Leiner Gelatins in Davenport, Iowa.

Sean Nichols has joined Gelest as Purchasing Manager, responsible for the procurement of raw materials for Gelest's manufacturing operations. He came to the company following a five-year tenure as Operations Manager in the manufacturing division of Haas Group International, based in West Chester, Pa.

Key promotions

Adrien Salomon has been promoted to Production Manager, with responsibility for managing day-to-day production activities and staff. He joined Gelest in 2004.

William Fry, who came to Gelest in 2010 as Assistant Controller, has been promoted to Controller. Prior to joining Gelest, he gained considerable experience in the auditing of manufacturing, distribution, construction, and not-for-profit organizations as a Senior Accountant for several accounting firms.

 

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read